While its exact mode of action in treating Parkinson's is not fully understood, it is thought to work by inhibiting MAO-B, ...

Cerebrospinal fluid (CSF) sampling demonstrated high levels of central nervous system (CNS) exposure with CVN293. Additional Cerevance Presentations at AAN 2025 The company presented a poster ...

Additional Cerevance Presentations at AAN 2025 The company presented a poster demonstrating the potential of its proprietary NETSseq platform to identify and/or validate cell-specific gene targets ...

Additional Cerevance Presentations at AAN 2025 The company presented a poster demonstrating the potential of its proprietary NETSseq platform to identify and/or validate cell-specific gene targets ...

Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled ...

KCNK13 was identified by Cerevance's proprietary NETSseq platform. About Solengepras (formerly CVN424) Solengepras is designed to provide a potentially novel approach to the treatment of Parkinson's ...